This article is more than 5 years old. Information may no longer be current.

Nicox initiates study of dual-action glaucoma drug

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Nicox S.A. has enrolled the first 10 patients in a phase 2 study of NCX 470, a nitric oxide-donating prostaglandin analog, for the reduction of IOP, according to a press release.

The multicenter, double-masked, parallel group, dose-ranging study will compare the safety and efficacy of NCX 470 against latanoprost 0.005% in 420 adults with open-angle glaucoma or ocular hypertension, the release said.

“NCX 470 is a new chemical entity which uses bimatoprost, a prostaglandin analog, as a scaffold for attaching an NO-donating moiety in order to achieve a dual mechanism of action,” the release stated.

The primary endpoint is mean reduction in diurnal IOP after 4 weeks of treatment.

“Based on our preclinical data, we believe that NCX 470 may provide a clinically meaningful improvement over the current standard of care, and become a first-line therapy for these patients,” Nicox chairman and CEO Michele Garufi said.